- Company
- LG Chem appeals... starts 2nd patent trial for Zemiglo
- by Kim, Jin-Gu Sep 12, 2024 05:50am
- The patent dispute over the use of DPP-4 inhibitor class diabetes drug Zemiglo (gemigliptin) is heading on to its second round. Generic companies have succeeded in winning both the evasion and invalidation trials regarding Zemiglo's use patent, after which LG Chem has appealed to the Intellectual Property High Court of Korea. According
- Company
- Which company will distribute Bayer's 'Canesten·Bepanthen'?
- by Nho, Byung Chul Sep 12, 2024 05:50am
- As the co-promotion agreement between Bayer and Il Dong Pharmaceutical for over the counter (OTC) medicines is set to expire, it gathers attention whether the company will renew the contract. According to industry sources, Bayer is searching for a new distributor to distribute its OTC medicines, Canesten and Bepanthen. Il Dong Pharmaceu
- Company
- GSK seeks mutual growth with its employees…top satisfaction
- by Hwang, Byung-woo Sep 11, 2024 04:39pm
- ‘Vaccine powerhouse’ is the first image that comes to mind upon the mention of GSK these days. The company has been constantly exerting its influence with its range of vaccines for various vaccine-preventable diseases. In the specialty medicine space, the company has expanded its pipeline to include respiratory asthma and COPD, as wel
- Company
- Pharma's China subsidiaries undergo massive changes
- by Kim, Jin-Gu Sep 11, 2024 05:54am
- China subsidiaries of South Korea's listed pharmaceutical and biotech companies are undergoing massive changes. Il-Yang Pharmaceutical and GC Biopharma have liquidated or sold their China subsidiaries within the past year. Hanmi Pharmaceutical (Hanmi Pharm)'s Beijing Hanmi Pharmaceutical, a local subsidiary of Hanmi Pharm in China, is a
- Opinion
- [Reporter's View] ‘Tyranny of Drug Committees persist'
- by Eo, Yun-Ho Sep 11, 2024 05:54am
- Even after a drug is approved by the Ministry of Food and Drug Safety and listed for reimbursement, the drug cannot be prescribed immediately by medical staff at general hospitals. A drug can only be prescribed at each hospital after a prescription code is generated upon review by their respective drug committees (DCs). The process, in
- Company
- Why SK Chemicals applied for EUA, not SK Biosicence
- by Kim, Jin-Gu Sep 11, 2024 05:54am
- SK Chemicals has applied for emergency use approval of the Novavax COVID-19 vaccine to the Ministry of Food and Drug Safety to introduce the vaccine to Korea. One interesting fact is that it was SK Chemicals, not SK Bioscience, that applied for the EUA. This is because the regulations for EUA require a prior record of vaccine imports. Sin
- Policy
- Price of Pristiq original and IMDs cut with generic release
- by Lee, Tak-Sun Sep 11, 2024 05:54am
- The release of generic versions of Pfizer's antidepressant ‘Pristiq ER Tab,’ has hit not only the sales of the original drug but also the salt-modified version. Korea Pharma launched the first generic version of Pristiq in Korea last month, and the release has also affected the salt-modified drug that was released 4 years ago. Accordi
- Company
- The export performance of biopharma is up
- by Kim, Jin-Gu Sep 10, 2024 05:48am
- The export performance of two out of three pharmaceutical and biotech companies is reported to have increased year-over-year (YoY). The total export sales of 24 companies increased from KRW 3.6869 trillion to KRW 4.8975 trillion over the year, up 33%. In particular, the export performance of Samsung Biologics, Celltrion, and SK Biopharm
- Company
- MS drug development poses a big challenge for pharma
- by Son, Hyung-Min Sep 10, 2024 05:48am
- Pharmaceutical companies based in South Korea and overseas are having difficulties developing new drugs for multiple sclerosis. Sanofi failed to demonstrate the drug's efficacy in some parts of clinical trials, and Merck's Phase 3 clinical trial did not meet primary endpoints. However, Sanofi announced that it will attempt to receive approv
- Company
- CAR-T cell therapy Yescarta expected to enter the KOR market
- by Eo, Yun-Ho Sep 10, 2024 05:48am
- Another new CAR-T cell therapy 'Yescarta' is anticipated to enter the Korean market. The Ministry of Food and Drug Safety (MFDS) recently posted that it has designated an orphan drug for Gilead Sciences' Yescarta (axicabtagene ciloleucel). The designated indication will include ▲Adult patients with relapsed or refractory diffuse lar
